A Prospective Study of Iridial Pigmentation and Eyelash Changes Due to Ophthalmic Treatment with Latanoprost

Japanese Journal of Ophthalmology

Volumn 48, Issue 2, 2004, Pages 141-147

  Chiba, Tatsuya ^a   Kashiwagi, Kenji ^a   Ishijima, Kiyotaka ^a   Furuichi, Mieko ^a   Kogure, Satoshi ^a   Abe, Keitetsu ^a   Chiba, Nami ^a   Tsukahara, Shigeo ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Eyelash change; Glaucoma; Iridial pigmentation; Japanese patients; Latanoprost

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; DIPIVEFRINE; LATANOPROST; PILOCARPINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; EYE COLOR; EYELASH; FEMALE; GLAUCOMA; HUMAN; INCIDENCE; INTRAOCULAR PRESSURE; IRIS; IRIS DISEASE; IRIS PIGMENTATION; JAPAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; EYE COLOR; EYELASHES; FEMALE; GLAUCOMA; HAIR COLOR; HAIR DISEASES; HUMANS; INTRAOCULAR PRESSURE; IRIS DISEASES; MALE; MELANOSIS; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTAGLANDINS F, SYNTHETIC;

EID: 1842450742     PISSN: 00215155     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10384-003-0039-6     Document Type: Article

References (22)

1. Camras CB, Alm A, Watson P, Stjernschantz J. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups. Ophthalmology 1996;103:1916-1924.
2. Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology 1996;103:126-137.
3. Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol 1997;41:S129-S138.
4. Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol 1997;124:544-547.
5. Wand M. Latanoprost and hyperpigmentation of eyelashes. Arch Ophthalmol 1997;115:1206-1208.
6. Wand M, Ritch R, Isbey EK Jr., Zimmerman TJ. Latanoprost and periocular skin color changes. Arch Ophthalmol 2001;119:614-615.
7. Teus MA, Arranz-Marquez E, Lucea-Suescun P. Incidence of iris colour change in latanoprost treated eyes. Br J Ophthalmol 2002;86:1085-1088.
8. Stjernschantz J, Albert D, Hu D, Drago F, Wistrand P. Mechanism and clinical significance of prostaglandin-induced iris pigmentation. Surv Ophthalmol 2002;47:S162.
9. Ogawa I, Imai K, Tsukano S. Latanoprost-induced iris and lid pigmentation and lid trichosis: two-year follow-up. J Eye 2002;19:377-381.
10. Hara T. Increased iris pigmentation after use of latanoprost in Japanese brown eyes. Nippon Ganka Gakkai Zasshi (J Jpn Ophthalmol Soc) 2001;105:314-321.
11. Chiba T, Kashiwagi K, Kogure S, et al. Iridial pigmentation induced by latanoprost ophthalmic solution in Japanese glaucoma patients. J Glaucoma 2001;10:406-410.
12. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:472-484.
13. Dieterich C. The fine structure of the melanocytes of the human iris. Graefes Arch Klin Ophthalmol 1972;183:317-333.
14. Prota G, Hu DN, Vincensi MR, McCormick SA, Napolitano A. Characterization of melanins in human irides and cultured uveal melanocytes from eyes of different colors. Exp Eye Res 1998;67:293-299.
15. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 1995;102:1743-1752.
16. Johnstone MA, Albert DM. Prostaglandin-induced hair growth. Surv Ophthalmol 2002;47:S185-S202.
17. Alm A, Camras CB, Watson PG. Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Surv Ophthalmol 1997;41:S105-S110.
18. Hara T, Kojima T. Evaluation of eyelash changes following topical treatment with latanoprost. Atarashii Ganka. (J Eye) 2000;17:1567-1570.
19. Selen G, Stjernschantz J, Resul B. Prostaglandin-induced iridial pigmentation in primates. Surv Ophthalmol 1997;41:S125-S128.
20. Drago F, Marino A, La Manna C. α-Methyl-p-tyrosine inhibits latanoprost-induced melanogenesis in vitro. Exp Eye Res 1999;68:85-90.
21. Kashiwagi K, Tsukamoto K, Suzuki M, Tsukahara S. Effects of isopropyl unoprostone and latanoprost on melanogenesis in mouse epidermal melanocytes. J Glaucoma 2002;11:57-64.
22. Kashiwagi K, Tsukamoto K, Wakamatsu K, et al. Effects of isopropyl unoprostone on melanogenesis in mouse epidermal melanocytes. Jpn J Ophthalmol 2001;45:259-263.